Company logo

PHAT - Phathom Pharmaceuticals, Inc.

NASDAQ -> Healthcare -> Biotechnology
Florham Park, United States
Type: Equity

PHAT price evolution
PHAT
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $384.26 $216.53 $249.38 $130.08
Short term investments
Net receivables $1.64
Inventory $9.44 $0.11 $0.11
Total current assets $397.43 $226.73 $257.72 $139.84
Long term investments
Property, plant & equipment $3.62 $3.66 $3.04 $3.36
Goodwill & intangible assets
Total noncurrent assets $16.41 $10.27 $7.32 $4.17
Total investments
Total assets $413.84 $236.99 $265.04 $144.01
Current liabilities
Accounts payable $12.6 $5.79 $4.17 $4.8
Deferred revenue
Short long term debt $0.73 $0.72 $0.72 $0.71
Total current liabilities $38.78 $23.98 $21.55 $14.44
Long term debt $438.12 $223.29 $218.39 $212.26
Total noncurrent liabilities $447.82 $230.79 $225.89 $219.76
Total debt $438.85 $224.01 $219.11 $212.97
Total liabilities $486.6 $254.76 $247.44 $234.21
Shareholders' equity
Retained earnings -$928.68 -$849.12 -$805.87 -$764.91
Other shareholder equity
Total shareholder equity -$72.76 -$17.77 $17.6 -$90.19
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $384.26 $155.89 $183.26 $287.5
Short term investments
Net receivables $1.64
Inventory $9.44
Total current assets $397.43 $160.51 $186.53 $291.37
Long term investments
Property, plant & equipment $3.62 $3.49 $2.56 $3.36
Goodwill & intangible assets
Total noncurrent assets $16.41 $4.3 $2.9 $3.74
Total investments
Total assets $413.84 $164.81 $189.43 $295.11
Current liabilities
Accounts payable $12.6 $10 $5.15 $16.78
Deferred revenue
Short long term debt $0.73 $0.71 $0.49 $7.83
Total current liabilities $38.78 $26.24 $18.92 $55.52
Long term debt $438.12 $204.79 $90.85 $41.19
Total noncurrent liabilities $447.82 $213.39 $98.35 $45.32
Total debt $438.85 $206.59 $91.34 $49.02
Total liabilities $486.6 $239.62 $117.28 $100.84
Shareholders' equity
Retained earnings -$928.68 -$727.09 -$529.37 -$385.49
Other shareholder equity
Total shareholder equity -$72.76 -$74.81 $72.16 $194.27
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue $0.68
Cost of revenue $0.17
Gross Profit $0.52
Operating activities
Research & development $13.39 $12.26 $12.76 $11.48
Selling, general & administrative $57 $23.4 $18.94 $18.6
Total operating expenses $70.39 $35.66 $31.7 $30.08
Operating income -$69.88 -$35.66 -$31.7 -$30.08
Income from continuing operations
EBIT -$66.54 -$33.14 -$31.35 -$28.6
Income tax expense
Interest expense $13.03 $10.11 $9.62 $9.22
Net income
Net income -$79.57 -$43.24 -$40.97 -$37.81
Income (for common shares) -$79.57 -$43.24 -$40.97 -$37.81
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $0.68
Cost of revenue $0.17
Gross Profit $0.52
Operating activities
Research & development $49.9 $71.44 $72.34 $98.15
Selling, general & administrative $117.93 $101 $62.74 $27.52
Total operating expenses $167.83 $172.44 $135.08 $125.67
Operating income -$167.31 -$172.44 -$135.08 -$125.67
Income from continuing operations
EBIT -$159.62 -$170.42 -$137.09 -$124.49
Income tax expense
Interest expense $41.97 $27.3 $6.79 $4.58
Net income
Net income -$201.59 -$197.72 -$143.88 -$129.07
Income (for common shares) -$201.59 -$197.72 -$143.88 -$129.07
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$79.57 -$43.24 -$40.97 -$37.81
Operating activities
Depreciation $0.18 $0.12 $0.12 $0.15
Business acquisitions & disposals
Stock-based compensation $24.58 $6.14 $7.25 $7.05
Total cash flows from operations -$43.8 -$31.91 -$22.2 -$39.67
Investing activities
Capital expenditures -$0.47 -$0.94 -$0.01 -$0.21
Investments
Total cash flows from investing -$0.47 -$0.94 -$0.01 -$0.21
Financing activities
Dividends paid
Sale and purchase of stock $0.01 $141.5 $14.07
Net borrowings $211.99
Total cash flows from financing $211.99 $0.01 $141.5 $14.07
Effect of exchange rate
Change in cash and equivalents $167.72 -$32.84 $119.3 -$25.81
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$201.59 -$197.72 -$143.88 -$129.07
Operating activities
Depreciation $0.57 $0.62 $0.52 $0.32
Business acquisitions & disposals
Stock-based compensation $45.02 $24.13 $16.81 $5.84
Total cash flows from operations -$137.58 -$146.53 -$148.62 -$69.69
Investing activities
Capital expenditures -$1.63 -$1.04 -$0.33 -$1.04
Investments
Total cash flows from investing -$1.63 -$1.04 -$0.33 -$1.04
Financing activities
Dividends paid
Sale and purchase of stock $155.59 $24.6 $1.94 $89.46
Net borrowings $211.99 $95.45 $42.76 $25
Total cash flows from financing $367.58 $120.04 $44.71 $114.46
Effect of exchange rate
Change in cash and equivalents $228.37 -$27.53 -$104.24 $43.73
Fundamentals
Market cap $581.83M
Enterprise value $636.42M
Shares outstanding 57.95M
Revenue $682.00K
EBITDA -$159.05M
EBIT -$159.62M
Net Income -$201.59M
Revenue Q/Q InfinityT%
Revenue Y/Y N/A
P/E ratio -2.89
EV/Sales 933.16
EV/EBITDA -4.00
EV/EBIT -3.99
P/S ratio 853.12
P/B ratio -8.00
Book/Share -1.26
Cash/Share 6.63
EPS -$3.48
ROA -76.08%
ROE 494.32%
Debt/Equity -6.69
Net debt/EBITDA -0.64
Current ratio 10.25
Quick ratio 10.00